AMGN241227C267500
- 0.01
- 0.000.00%
Amgen Newsroom
Bernstein Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Amgen Is Maintained at Equal-Weight by Wells Fargo
Wells Fargo Maintains Amgen(AMGN.US) With Hold Rating, Cuts Target Price to $280
Express News | Amgen Inc. : Wells Fargo Cuts Target Price to $280 From $335
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Goldman Sachs lowered Amgen's Target Price to $370.
Gelonghui, January 9 | Goldman Sachs: Downgraded Amgen's Target Price from $375 to $370, maintaining a "Buy" rating. (Gelonghui)
Goldman Sachs Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $370
Goldman Sachs Adjusts Price Target on Amgen to $370 From $375, Maintains Buy Rating
Merck Downgraded by Truist to Hold Over Growth Concerns
Asher Bio Announces Clinical Trial Collaboration And Supply Agreement With Amgen On Etakafusp Alfa In Combination With Bispecific T-cell Engager In Patients With Small Cell Lung Cancer
Truist Financial Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $298
Amgen Analyst Ratings
AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Truist Financial Maintains Amgen(AMGN.US) With Hold Rating, Announces Target Price $298
FDA Issues Draft Guidance on Developing Weight Loss Drugs
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $324
RBC Trims Price Target on Amgen to $324 From $330, Keeps Outperform Rating
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Amgen (NASDAQ:AMGN) Is Paying Out A Larger Dividend Than Last Year
Express News | Amgen UK: Imdylltra Granted Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in UK